Page 81 - Clinical Olfactory Working Group Consensus Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical olfactory working group consensus statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Olfactory Working Group Consensus Statement Today - Breaking & Trending Today

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

New studies mark an important advancement of Boehringer Ingelheim's cardiometabolic focus areas obesity and NASH. The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on ....

United States , Virginia Commonwealth University , David Rosen , Birgit Leimer , Waheed Jamal , Boehringer Ingelheim , Arunj Sanyal , Adam Steensberg , Zealand Pharma , Product Communications , Boehringer Ingelheim Corporate Center Gmb , Molecular Pathology , Virginia Commonwealth University School , Executive Vice President , Chief Medical Officer , Respiratory Medicine , Communications Manager , Ingelheim Corporate Center Gmbh , ஒன்றுபட்டது மாநிலங்களில் , வர்ஜீனியா காமன்வெல்த் பல்கலைக்கழகம் , டேவிட் ரோஸன் , வீத் ஜமால் , போஹெரிங்கர் இஂகல்‌ஹைம் , ஜீலாந்து பார்மா , ப்ராடக்ட் தகவல்தொடர்புகள் , போஹெரிங்கர் இஂகல்‌ஹைம் பெருநிறுவன மையம் க்ம்ப் ,

Lyra Therapeutics : Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual

New data presented includes:
- First product candidate found to be effective in non-polyp patients in addition to polyp patients in a clinical trial, based on 100% of patients in both groups achieving SNOT-22 MCID at week 24 with LYR-210 (7500µg group) -
- LYR-210 (7500µg) decreased ethmoid opacification at week 24, a measure of disease modification -
- LYR-210 (7500µg) reduced the need for rescue medication -
- Separately, Lyra also reported an analysis showing that LYR-210 (7500µg) achieved statistically significant improvement across 3 cardinal symptoms at week 24 in the LANTERN study -
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today presented data from its Phase 2 LANTERN study of LYR-210, the company’s lead long-acting product candidate fo ....

Robert Kern , Anders Cervin , Maria Palasis , Rodney Williams Memorial Foundation , University Of Queensland , Lyra Therapeutics Inc , Lyra Therapeutics , Combined Otolaryngology Spring Meetings , Professor Anders Cervin , Garnett Passe , Rodney Williams Memorial Foundation Chair , Principal Investigator , Oral Presentation , Non Polyp Patients , Cardinal Symptoms , Chief Medical Officer , Chief Executive Officer , Inc Stock Exchange , Press Release , Both Lyra , ராபர்ட் கர்ன் , ரோட்னி வில்லியம்ஸ் நினைவகம் அடித்தளம் , பல்கலைக்கழகம் ஆஃப் குயின்ஸ்லாந்து , லைரா சிகிச்சை இன்க் , லைரா சிகிச்சை , கார்னெட் கடந்த காலம் ,

Welcome To IANS Live - SCIENCE - Antipsychotics can lower Covid infection, severity risk: Study

Photo Credit: IANS
IANSLive
London, April 12 (IANS) Patients treated with antipsychotic drugs have a lower risk of becoming infected or suffer a milder form of SARS-CoV-2 the virus causing Covid-19 if they get infected, according to a study.
To get full access of the story, click here to subscribe to IANS News Service
© 2021 IANS India Private Limited. All Rights Reserved.
The reproduction of the story/photograph in any form will be liable for legal action.
For news, views and gossips, follow IANS at Twitter.
Update: 12-April-2021 ....

City Of , United Kingdom , News Service , India Private , All Rights , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , செய்தி சேவை , இந்தியா ப்ரைவேட் , அனைத்தும் உரிமைகள் ,

Applied DNA Sciences, Inc. and Takis Biotech/Evvivax: Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA COVID-19 Vaccine Candidate in Felines

Applied DNA Sciences, Inc. and Takis Biotech/Evvivax: Applied DNA and Evvivax Announce Positive Preliminary Results of Phase I Clinical Trial for LinearDNA COVID-19 Vaccine Candidate in Felines
- Strong Neutralizing Antibody Titer Elicited Across Cohort -
Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company ), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. ( Evvivax ), today announced positive preliminary Phase I clinical trial results for a LinearDNA COVID-19 vaccine candidate (the vaccine candidate ) in adult domestic felines. Results following administration of a single prime dose of the vaccine candidate on day 1 in late February indicate that the LinearDNA vaccine candidate is well-tolerated by the cohort. A SARS-CoV-2 neutralization assay was conducted by the Cornell University Animal Health Diagnostic Center at the College of Veterinary Medicine 20 days after prime dose ....

United Kingdom , Joseph Impellizeri , Jamesa Hayward , Antonella Conforti , Luigi Aurisicchio , Us Department Of Agriculture , Sciences Inc , Drug Administration , Securities Exchange , Cornell University Animal Health Diagnostic Center , College Of Veterinary Medicine , Candidate Well Tolerated , Polymerase Chain Reaction , Veterinary Medicine , Diego Diel , Associate Professor , Cornell University College , Population Medicine , Guardian Veterinary Specialists , Trial Supervising Investigator , Takis Biotech , Coronavirus Variant Found , First Time , Russell Microcap , Therapeutic Veterinary Cancer Vaccines , Securities Act ,

MAGI Announces: MAGI's Clinical Research vConference — Spring 2021 April 26-29 and May... ( FALLS C...)

MAGI’s Clinical Research vConference Spring 2021
April 26-29 and May 3-6, 2021 • Join Us Virtually
Want to solve the biggest clinical trial challenges? The answers are at MAGI’s Clinical Research vConference Spring 2021.
With 70+ sessions over eight days delivering a multitude of practical information using real-life examples, 180+ highly rated speakers with diverse expertise and backgrounds, and lots of time for audience interaction, attendees will find and be able to implement solutions that work. In fact, MAGI attendees gather an average of 10 practical tips to implement in their own organizations.
Sessions come in multiple tracks (with the potential for 90+ continuing education contact hours!) to help hone in on exactly what is needed: Clinical Operations & Project Management, Quality & Risk Management, Site Management, Contracts, Budgets & Billing, Regulatory Compliance and Management & Professional Skills. An eighth track, Special Topics, add ....

Paperless Clinical Research , Clinical Research , A Panel Discussion , Diversity Inclusion In Clinical Research , Join Us Virtually , Clinical Operations , Project Management , Risk Management , Site Management , Regulatory Compliance , Special Topics , Decentralizing Clinical Trials , Panel Discussion , Can Wreak Havoc , Health Literacy Strategies , Clarify Your Study Communications , Paperless Clinical Research Studies , Conference Details , Access Pass , Magi S , 26 29 , 3 6 , Medical News Today , Latest Medical News , Medical Newsletters , Current Medical News ,